Cell and Gene Therapy Global Market Report 2023 – Cell and Gene Therapy Global Market Report 2023 – By Product (Cell Therapy, Gene Therapy), By Application (Oncology, Dermatology, Musculoskeletal, Other Applications), By End User (Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users) – Market Size, Trends, And Global Forecast 2023-2032 ...(expand)

Gene therapy involves the transmission of genetic material, typically in the form of a carrier or vector, and the uptake of the gene into the proper body cells. Cell therapy includes introducing cells into the patient with the appropriate function. Some procedures combine cell therapy with gene therapy. For further insights on the cell and gene therapy market, request a sample here

The cell and gene therapy market growth is aided by steady investment and consolidation in cell and gene therapies. However, some cell and gene therapy market restraints include limited reimbursements preventing patients from receiving treatments. For further insights on the cell and gene therapy market, request a sample here

The cell and gene therapy market is expected to reach $26.21 billion in 2027 at a rate of 24.4%. For further insights on the cell and gene therapy market, request a sample here

The global cell and gene therapy market is segmented as
1) By Product: Cell Therapy, Gene Therapy
2) By Application: Oncology, Dermatology, Musculoskeletal, Other Applications
3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users
For further insights on the cell and gene therapy market, request a sample here

North America was the largest region in the cell and gene therapy market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

Key competitors in the cell and gene therapy market are, Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Merck, Organogenesis Holdings, Dendreon, Vericel, Bluebird Bio, Fibrocell Science, Biogen, Pfizer, ViroMed, Advantagene, Advaxis, Alnylam Pharmaceuticals, AnGes USA, Anterogen, Atara Therapeutics, Athersys, AveXis, BioCardia, BioMarin Pharmaceuticals, BrainStorm Cell Therapeutics, Caladrius Bioscience, Celyad, Cook MyoSite, Cytori Therapeutics, Ferring Pharmaceuticals, Gamida Cell. For further insights on the cell and gene therapy market, request a sample here.

Major trends influencing the cell and gene therapy market include chimeric antigen receptor (CAR) T-cell therapy. (CAR) T-cell therapy is a combination of cell and gene therapy in which T cells are collected from the patient’s blood and are genetically engineered to produce modified receptors at their surface, known as chimeric antigen receptors (CARs). These modified T cells have special structures (receptors) and are reinfused into the patient. Then, the modified receptors of T cells help in targeting the surface antigen of the cancer cell, ultimately resulting in the killing of tumour cells in patients. For further insights on the cell and gene therapy market, request a sample here.

For detailed insights on the major opportunities and strategies in the cell and gene therapy market, request a sample here.

For detailed insights on cell and gene therapy market's relation to the overall economy and other similar markets, request a sample here.

For detailed insights on the mergers and acquisitions in the cell and gene therapy industry, request a sample here.

For detailed insights on the key dynamics influencing the cell and gene therapy market growth and SWOT analysis of the cell and gene therapy industry, request a sample here.